News and Updates

AstraZeneca and AC Health form a strategic partnership to expand clinical trial capabilities in the Philippines, promising faster access to new therapies.

New research shows MRI surveillance alone is safer than radiation for SCLC patients, preserving cognitive health without compromising survival outcomes.

Sponsors are being flooded with new AI clinical data tools. Before signing, ensure you understand the essential risks regarding compliance, bias, and scale.

New data shows Tam-Peli extends survival to 13.3 months in relapsed small-cell lung cancer, marking a potential breakthrough for aggressive lung malignancy.

New trial data confirms amivantamab plus chemotherapy extends overall survival to 34.3 months for patients with EGFR exon 20 insertion-positive NSCLC.

New trial data shows ivonescimab outperforms pembrolizumab in NSCLC, reducing disease progression risk by 27%. Discover the impact of this bispecific drug.

Phase 3 trial results show trastuzumab botidotin offers superior 11.1-month PFS compared to T-DM1, marking a major milestone in HER2-positive breast cancer.

Telix Pharmaceuticals receives FDA approval for a groundbreaking brain cancer imaging agent, set to improve diagnostic precision for glioma patients.

AstraZeneca’s breast cancer drug Dato-DXd has missed its primary goal in a Phase 3 trial. Read the latest clinical implications for oncology treatment.

Treating clinical trials as high-stakes bets threatens medical integrity. Learn why prioritizing scientific rigor over speculation is vital for patient care.